Supplementary Data from Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab

Abstract

Supplemental Methods; Supplemental Figure legends; Supplemental Table 1; Figure S1, S2, S3, S4, S5, S6, S7, S8 and S9